Calcimedica announces appointment of dr. alan glicklich to board of directors

La jolla, calif., jan. 14, 2025 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of alan glicklich, m.d.

CALC Ratings Summary

CALC Quant Ranking